An H X, Niederacher D, Dominik S I, Kuschel B, Yan H, Dall P, Schnürch H G, Bender H G, Beckmann M W
Department of Obstetrics and Gynecology, Heinrich-Heine Universität, Düsseldorf, Germany.
Anticancer Res. 1997 Jul-Aug;17(4B):3133-6.
Gene amplification is a common mechanism of proto-oncogene activation and contributes to tumor progression. Analysis of such genetic alterations is relevant to our understanding of tumor genetics and can provide prognostic information for the patients. A rapid, non-radioactive approach based on qdPCR and fluorescent DNA technique was applied for determination of int-2 and c-erbB2 gene amplification and correlated with other prognostic factors in 70 breast cancer samples. ER and PgR were analysed by immunohistochemistry. The mixed template assay showed 96% concordance between calculated and measured gene copy number. int-2 gene and c-erbB2 amplification were both found in 24% of the tumors. The amplification did not correlate with any of the other prognostic factors. 8% of the tumors showed amplification of both genes without significant correlations to any of the other parameters. The fd-PCR assay is a valuable tool for determination of amplification of int-2 and c-erbB2 genes. Therefore, more detailed information about individual tumour biology and outcome may be acquired by this routine assay and probably provide prognostic impact.
基因扩增是原癌基因激活的常见机制，并且促进肿瘤进展。对这类基因改变的分析与我们对肿瘤遗传学的理解相关，并且能够为患者提供预后信息。一种基于定量数字PCR（qdPCR）和荧光DNA技术的快速、非放射性方法被应用于测定70例乳腺癌样本中的int-2和c-erbB2基因扩增情况，并与其他预后因素进行关联分析。雌激素受体（ER）和孕激素受体（PgR）通过免疫组织化学进行分析。混合模板检测显示计算的基因拷贝数与测量的基因拷贝数之间有96%的一致性。在24%的肿瘤中均发现了int-2基因和c-erbB2扩增。这种扩增与任何其他预后因素均无相关性。8%的肿瘤显示两个基因均扩增，且与任何其他参数均无显著相关性。荧光数字PCR（fd-PCR）检测是测定int-2和c-erbB2基因扩增的一种有价值的工具。因此，通过这种常规检测可能会获得有关个体肿瘤生物学特性和转归的更详细信息，并且可能提供预后影响。
